Skip to main content

Advertisement

SpringerLink
Log in

The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs

  • Review
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

Epilepsy is a neurologic disorder affecting approximately 50 million people worldwide, or about 0.7% of the population [1]. Thus, the use of anticonvulsant drugs in the treatment of epilepsy is common and widespread. There are three generations of anticonvulsant drugs, categorized by the year in which they were developed and released. The aim of this review is to discuss the pharmacokinetics, drug-drug interactions, and adverse events of the third generation of anticonvulsant drugs. Where available, overdose data will be included. The pharmacokinetic properties of third-generation anticonvulsant drugs include relatively fewer drug-drug interactions, as well as several unique and life-threatening adverse events. Overdose data are limited, so thorough review of adverse events and knowledge of drug mechanism will guide expectant management of future overdose cases. Reporting of these cases as they occur will be necessary to further clarify toxicity of these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. Epilepsy Fact Sheet [updated February 2017. Available from: http://www.who.int/mediacentre/factsheets/fs999/en/.

  2. Helmers SL, Thurman DJ, Durgin TL, Pai AK, Faught E. Descriptive epidemiology of epilepsy in the U.S. population: a different approach. Epilepsia. 2015;56(6):942–8.

    Article  PubMed  Google Scholar 

  3. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus—report of the ILAE task force on classification of status Epilepticus. Epilepsia. 2015;56(10):1515–23.

    Article  PubMed  Google Scholar 

  4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–9.

    Article  CAS  PubMed  Google Scholar 

  5. Abou-Khalil BW. Antiepileptic drugs. Continuum (Minneapolis, Minn). 2016;22(1 Epilepsy):132–56.

  6. Sirven JI. Management of epilepsy comorbidities. Continuum (Minneapolis, Minn). 2016;22(1 Epilepsy):191–203.

  7. LACOSAMIDE oral solution, CV [PDF]. 20016 [updated 04/2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204839s000lbl.pdf.

  8. Vimpat (Lacosamide). In: Pharma U, editor. 2014.

  9. Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54(3):393–404.

    Article  PubMed  CAS  Google Scholar 

  10. Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123(2):137–41.

    Article  CAS  PubMed  Google Scholar 

  11. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T. Lacosamide: a review of preclinical properties. CNS drug reviews. 2007;13(1):21–42.

    Article  CAS  PubMed  Google Scholar 

  12. Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015;54(9):901–14.

    Article  CAS  PubMed  Google Scholar 

  13. Cawello W, Fuhr U, Hering U, Maatouk H, Halabi A. Impact of impaired renal function on the pharmacokinetics of the antiepileptic drug lacosamide. Clin Pharmacokinet. 2013;52(10):897–906.

    Article  CAS  PubMed  Google Scholar 

  14. Boyd M, Proschek C, Kazzi Z. 2014 annual meeting of the north American congress of clinical toxicology (NACCT). Abstract: massive lacosamide overdose treated with continuous renal replacement therapy. Clin Toxicol. 2014;52(7):757–8.

    Google Scholar 

  15. Charlton N, Holstege C. Abstracts of the XXVIII international congress of the European Association of Poison Centres and Clinical Toxicologists, May 6–9, 2008, Seville, Spain. Abstract: lacosamide overdose induced status epilepticus treated with hemodialysis. Clin Toxicol. 2008;46(5):351–421.

    Article  Google Scholar 

  16. Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol. 2012;52(11):1739–48.

    Article  CAS  PubMed  Google Scholar 

  17. Cawello W, Mueller-Voessing C, Andreas JO. Effect of lacosamide on the steady-state pharmacokinetics of digoxin: results from a phase I, multiple-dose, double-blind, randomised, placebo-controlled, crossover trial. Clin Drug Investig. 2014;34(5):327–34.

    Article  CAS  PubMed  Google Scholar 

  18. Cawello W, Mueller-Voessing C, Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial. Clin Drug Investig. 2014;34(5):317–25.

    Article  CAS  PubMed  Google Scholar 

  19. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50(4):459–71.

    Article  CAS  PubMed  Google Scholar 

  20. Cawello W, Rosenkranz B, Schmid B, Wierich W. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. Epilepsia. 2013;54(3):530–6.

    Article  CAS  PubMed  Google Scholar 

  21. Stockis A, van Lier JJ, Cawello W, Kumke T, Eckhardt K. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. Epilepsia. 2013;54(7):1161–6.

    Article  CAS  PubMed  Google Scholar 

  22. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308–17.

    Article  CAS  PubMed  Google Scholar 

  23. Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy & behavior : E&B. 2015;52(Pt A):119–27.

    Article  Google Scholar 

  24. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443–53.

    Article  CAS  PubMed  Google Scholar 

  25. Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a phase III open-label extension trial. Epilepsia. 2012;53(3):521–8.

    Article  CAS  PubMed  Google Scholar 

  26. Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd GD. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures. Epilepsia. 2013;54(1):58–65.

    Article  CAS  PubMed  Google Scholar 

  27. Rudd GD, Haverkamp W, Mason JW, Wenger T, Jay G, Hebert D, et al. Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures. Acta Neurol Scand. 2015;132(5):355–63.

    Article  CAS  PubMed  Google Scholar 

  28. Kellinghaus C. Reversible suicidal ideation after exposure to lacosamide. Seizure. 2013;22(4):318–9.

    Article  PubMed  Google Scholar 

  29. Pinkhasov A, Lam T, Hayes D, Friedman M, Singh D, Cohen H. Lacosamide induced psychosis: case report, review of differential diagnosis and relevant pharmacokinetics. Clin Neuropharmacol. 2015;38(5):198–200.

    Article  PubMed  Google Scholar 

  30. Deslandes G, Bouquié R, Lorber J, Bruneau C, Gregoire M, Grison-Hernando H, et al. Status epilepticus following self-poisoning of lacosamide and lamotrigine: a case report with follow-up of drug serum concentrations. Toxicologie Analytique et Clinique. 2015;27(2):88–90.

    Article  Google Scholar 

  31. Bauer S, David Rudd G, Mylius V, Hamer HM, Rosenow F. Lacosamide intoxication in attempted suicide. Epilepsy Behavior. 2010;17(4):549–51.

    Article  PubMed  Google Scholar 

  32. Sunwoo JS, Byun JI, Lee SK. A case of lacosamide-induced hepatotoxicity. Int J Clin Pharmacol Ther. 2015;53(6):471–3.

    Article  PubMed  Google Scholar 

  33. del Val AA, Ble Caso M, Higon Ballester MD, Ortuno Cortes JA. Lacosamide-induced acute pancreatitis with positive rechallenge test. J Clin Gastroenterol. 2014;48(7):651.

    Google Scholar 

  34. Jones GL, Popli GS, Silvia MT. Lacosamide-induced valproic acid toxicity. Pediatr Neurol. 2013;48(4):308–10.

    Article  PubMed  Google Scholar 

  35. Chinnasami S, Rathore C, Duncan JS. Sinus node dysfunction: an adverse effect of lacosamide. Epilepsia. 2013;54(6):e90–3.

    Article  CAS  PubMed  Google Scholar 

  36. Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010;18(3):322–4.

    Article  PubMed  Google Scholar 

  37. Malissin I, Baud FJ, Deveaux M, Champion S, Deye N, Megarbane B. Fatal lacosamide poisoning in relation to cardiac conduction impairment and cardiovascular failure. Clinical toxicology (Philadelphia, Pa). 2013;51(4):381–2.

    Article  CAS  Google Scholar 

  38. Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav. 2011;20(4):725–7.

    Article  PubMed  Google Scholar 

  39. APTIOM® (eslicarbazepine acetate) tablet Marlborough, MA 01752 USA Sunovion Pharmaceuticals Inc; 2015 [Available from: http://www.aptiom.com/Aptiom-Prescribing-Information.pdf.

  40. Grunze H, Kotlik E, Costa R, Nunes T, Falcao A, Almeida L, et al. Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. J Affect Disord. 2015;174:70–82.

    Article  CAS  PubMed  Google Scholar 

  41. Nath K, Bhattacharya A, Praharaj SK. Eslicarbazepine acetate in the management of refractory bipolar disorder. Clin Neuropharmacol. 2012;35(6):295.

    Article  PubMed  Google Scholar 

  42. Almeida L, Falcao A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005;45(9):1062–6.

    Article  CAS  PubMed  Google Scholar 

  43. Almeida L, Minciu I, Nunes T, Butoianu N, Falcao A, Magureanu SA, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol. 2008;48(8):966–77.

    Article  CAS  PubMed  Google Scholar 

  44. Ley M, Principe A, Jimenez-Conde J, Rocamora R. Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests. Epilepsy Res. 2015;115:147–52.

    Article  CAS  PubMed  Google Scholar 

  45. Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R&D. 2016;16(4):303–16.

    Article  CAS  Google Scholar 

  46. Maia J, Almeida L, Falcao A, Soares E, Mota F, Potgieter MA, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther. 2008;46(3):119–30.

    Article  CAS  PubMed  Google Scholar 

  47. Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64(3):267–73.

    Article  CAS  PubMed  Google Scholar 

  48. Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409–31.

    PubMed  Google Scholar 

  49. Falcao A, Pinto R, Nunes T, Soares-da-Silva P. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res. 2013;106(1–2):244–9.

    Article  CAS  PubMed  Google Scholar 

  50. Nunes T, Sicard E, Almeida L, Falcao A, Rocha JF, Brunet JS, et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin. 2010;26(6):1355–62.

    Article  CAS  PubMed  Google Scholar 

  51. Verrotti A, Loiacono G, Rossi A, Zaccara G. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy. Epilepsy Res. 2014;108(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  52. Villanueva V, Serratosa JM, Guillamon E, Garces M, Giraldez BG, Toledo M, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res. 2014;108(7):1243–52.

    Article  CAS  PubMed  Google Scholar 

  53. Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013;22(7):528–36.

    Article  PubMed  Google Scholar 

  54. Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56(2):244–53.

    Article  CAS  PubMed  Google Scholar 

  55. Vaz-Da-Silva M, Nunes T, Almeida L, Gutierrez MJ, Litwin JS, Soares-Da-Silva P. Evaluation of Eslicarbazepine acetate on cardiac repolarization in a thorough QT/QTc study. J Clin Pharmacol. 2012;52(2):222–33.

    Article  CAS  PubMed  Google Scholar 

  56. Gupta DK, Bhoi SK, Kalita J, Misra UK. Hyponatremia following esclicarbazepine therapy. Seizure. 2015;29:11–4.

    Article  PubMed  Google Scholar 

  57. Massot A, Gimenez-Arnau A. Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine. J Pharmacol Pharmacother. 2014;5(4):271–4.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Alcantara-Reifs CM, Salido-Vallejo R, Garnacho-Saucedo G, de la Corte-Sanchez S, Velez G-NA. Eslicarbazepine-induced toxic epidermal necrolysis. Epilepsia. 2016;57(5):854–5.

    Article  PubMed  Google Scholar 

  59. BANZEL® (rufinamide) 2010 [updated October 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021911s005lbl.pdf.

  60. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141–58.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49(7):1123–41.

    Article  CAS  PubMed  Google Scholar 

  62. Biton V, Krauss G, Vasquez-Santana B, Bibbiani F, Mann A, Perdomo C, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011;52(2):234–42.

    CAS  PubMed  Google Scholar 

  63. Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia. 2009;50(8):1899–909.

    Article  CAS  PubMed  Google Scholar 

  64. Coppola G, Grosso S, Franzoni E, Veggiotti P, Zamponi N, Parisi P, et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol. 2011;18(2):246–51.

    Article  CAS  PubMed  Google Scholar 

  65. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950–8.

    Article  CAS  PubMed  Google Scholar 

  66. Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010;122(3):202–8.

    Article  CAS  PubMed  Google Scholar 

  67. Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res. 2014;108(9):1627–36.

    Article  CAS  PubMed  Google Scholar 

  68. Palhagen S, Canger R, Henriksen O, van Parys JA, Riviere ME, Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res. 2001;43(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  69. Alsaad AM, Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol. 78(6):1264–71.

  70. Elger CE, Stefan H, Mann A, Narurkar M, Sun Y, Perdomo C. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010;88(2–3):255–63.

    Article  CAS  PubMed  Google Scholar 

  71. Shahbaz S, Sivamani RK, Konia T, Burrall B. A case of drug rash with eosinophilia and systemic symptoms (DRESS) related to rufinamide. Dermatol Online J. 2013;19(4):4.

    CAS  PubMed  Google Scholar 

  72. Chambel M, Mascarenhas MI, Regala J, Gouveia C, Prates S. Clinical Stevens-Johnson syndrome and rufinamide: a clinical case. Allergol Immunopathol. 2013;41(1):68–9.

    Article  CAS  Google Scholar 

  73. Kaufman KR, Struck PJ. Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder. Epilepsy Behav. 2011;20(2):386–9.

    Article  PubMed  Google Scholar 

  74. Drake K, Labiner DM. Severe constipation associated with the use of rufinamide (Banzel) in an adolescent. Epilepsy Behav. 2010;18(1–2):132.

    Article  PubMed  Google Scholar 

  75. Ide M, Kato T, Nakata M, Saito K, Yoshida T, Awaya T, et al. A granulocytosis associated with rufinamide: a case report. Brain Dev. 2015;37(8):825–8.

    Article  PubMed  Google Scholar 

  76. Schimpf R, Veltmann C, Papavassiliu T, Rudic B, Goksu T, Kuschyk J, et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm. 2012;9(5):776–81.

    Article  PubMed  PubMed Central  Google Scholar 

  77. BRIVIACT Smyrna, GA 30080: UCB; 2016 [updated 02/2016. highlights of prescribing information ]. Available from: www.accessdata.fda.gov/drugsatfda.

  78. Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1–3):36–44.

    Article  CAS  PubMed  Google Scholar 

  79. Ferlazzo E, Russo E, Mumoli L, Sueri C, Gasparini S, Palleria C, et al. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2015;11:2967–73.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Stockis A, Watanabe S, Rouits E, Matsuguma K, Irie S. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. Drug Metab Pharmacokinetics. 2014;29(5):394–9.

    Article  CAS  Google Scholar 

  81. Stockis A, Watanabe S, Scheen AJ. Effect of brivaracetam on CYP3A activity, measured by oral midazolam. J Clin Pharmacol. 2015;55(5):543–8.

    Article  CAS  PubMed  Google Scholar 

  82. Stockis A, Watanabe S, Scheen AJ, Tytgat D, Gerin B, Rosa M, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Disposition. 2016;44(6):792–9.

    Article  CAS  Google Scholar 

  83. Stockis A, Chanteux H, Rosa M, Rolan P. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19–27.

    Article  CAS  PubMed  Google Scholar 

  84. Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57–66.

    Article  CAS  PubMed  Google Scholar 

  85. French JA, Costantini C, Brodsky A, von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75(6):519–25.

    Article  CAS  PubMed  Google Scholar 

  86. Kalviainen R, Genton P, Andermann E, Andermann F, Magaudda A, Frucht SJ, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia. 2016;57(2):210–21.

    Article  PubMed  CAS  Google Scholar 

  87. Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–8.

    Article  CAS  PubMed  Google Scholar 

  88. Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55(1):38–46.

    Article  CAS  PubMed  Google Scholar 

  89. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47–56.

    Article  CAS  PubMed  Google Scholar 

  90. Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89–97.

    Article  PubMed  CAS  Google Scholar 

  91. Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007;63(6):680–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. FYCOMPA® (perampanel) tablets Woodcliff Lake, NJ 07677: Eisai Inc; 2015 [Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202834s005lbl.pdf.

  93. Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61(4):517–22.

    Article  CAS  PubMed  Google Scholar 

  94. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 2010;92(2–3):89–124.

    Article  PubMed  Google Scholar 

  95. Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12–27.

    Article  CAS  PubMed  Google Scholar 

  96. French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy a randomized trial. Neurology. 2015;85(11):950–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Lagae L, Villanueva V, Meador KJ, Bagul M, Laurenza A, Kumar D, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016;57(7):1120–9.

    Article  CAS  PubMed  Google Scholar 

  98. Rohracher A, Brigo F, Hofler J, Kalss G, Neuray C, Dobesberger J, et al. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother. 2016;17(10):1403–11.

    Article  CAS  PubMed  Google Scholar 

  99. Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2015;8(6):733–40.

    Article  CAS  PubMed  Google Scholar 

  100. Shimabukuro K, Gibbon F, Kerstetter J, Tinsley C, Ashwal S. DRESS associated with perampanel administration in a child with drug-resistant epilepsy. Neurology. 2014;83(23):2188.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Yang H, Laurenza A, Williams B, Patten A, Hussein Z, Ferry J. Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure phase III clinical trials. Epilepsy Res. 2015;114:122–30.

    Article  CAS  PubMed  Google Scholar 

  102. Meador KJ, Yang H, Pina-Garza JE, Laurenza A, Kumar D, Wesnes KA. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57(2):243–51.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Coyle H, Clough P, Cooper P, Mohanraj R. Clinical experience with perampanel: focus on psychiatric adverse effects. Epilepsy Behav. 2014;41:193–6.

    Article  PubMed  Google Scholar 

  105. Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55(Suppl 1):13–5.

    Article  CAS  PubMed  Google Scholar 

  106. Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. 2013;54(1):126–34.

    Article  CAS  PubMed  Google Scholar 

  107. Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–15.

    Article  CAS  PubMed  Google Scholar 

  108. French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117–25.

    Article  CAS  PubMed  Google Scholar 

  109. Rektor I, Krauss GL, Bar M, Biton V, Klapper JA, Vaiciene-Magistris N, et al. Perampanel study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126(4):263–9.

    CAS  PubMed  Google Scholar 

  110. Huber B. Increased risk of suicidality on perampanel (Fycompa(R))? Epilepsy Behav. 2014;31:71–2.

    Article  PubMed  Google Scholar 

  111. Hoppner AC, Fauser S, Kerling F. Clinical course of intoxication with the new anticonvulsant drug perampanel. Epileptic Disord. 2013;15(3):362–4.

    PubMed  Google Scholar 

  112. SABRIL® (vigabatrin) [PDF]. 2016 [updated June 2016. Available from: http://www.lundbeck.com/upload/us/files/pdf/Products/Sabril_PI_US_EN.pdf.

  113. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol. 1989;27(Suppl 1):19s–22s.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. French JA. Vigabatrin Epilepsia. 1999;40(Suppl 5):S11–6.

    Article  CAS  PubMed  Google Scholar 

  115. Bartoli A, Gatti G, Cipolla G, Barzaghi N, Veliz G, Fattore C, et al. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia. 1997;38(6):702–7.

    Article  CAS  PubMed  Google Scholar 

  116. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. British journal of clinical pharmacology. 1989;27(Suppl 1):27s–33s.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. The Cochrane database of systematic reviews. 2013(1):Cd007302.

  118. Clayton LM, Stern WM, Newman WD, Sander JW, Acheson J, Sisodiya SM. Evolution of visual field loss over ten years in individuals taking vigabatrin. Epilepsy Res. 2013;105(3):262–71.

    Article  CAS  PubMed  Google Scholar 

  119. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ (Clinical research ed). 1997;314(7075):180–1.

    Article  CAS  Google Scholar 

  120. Kalviainen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS drugs. 2001;15(3):217–30.

    Article  CAS  PubMed  Google Scholar 

  121. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998;50(3):614–8.

    Article  CAS  PubMed  Google Scholar 

  122. Nicolson A, Leach JP, Chadwick DW, Smith DF. The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry. 2002;73(3):327–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Milh M, Villeneuve N, Chapon F, Pineau S, Lamoureux S, Livet MO, et al. Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin. J Child Neurol. 2009;24(3):305–15.

    Article  PubMed  Google Scholar 

  124. Wheless JW, Carmant L, Bebin M, Conry JA, Chiron C, Elterman RD, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50(2):195–205.

    Article  CAS  PubMed  Google Scholar 

  125. Fong CY, Osborne JP, Edwards SW, Hemingway C, Hancock E, Johnson AL, et al. An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. Dev Med Child Neurol. 2013;55(9):862–7.

    Article  PubMed  Google Scholar 

  126. Hernandez Vega Y, Kaliakatsos M, UK-I JM, Lascelles K, Lim M. Reversible vigabatrin-induced life-threatening encephalopathy. JAMA Neurol. 2014;71(1):108–9.

    Article  PubMed  Google Scholar 

  127. Schonstedt V, Stecher X, Venegas V, Silva C. Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms. Neuroradiol J. 2015;28(5):515–8.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Haas-Lude K, Wolff M, Riethmuller J, Niemann G, Krageloh-Mann I. Acute encephalopathy associated with vigabatrin in a six-month-old girl. Epilepsia. 2000;41(5):628–30.

    Article  CAS  PubMed  Google Scholar 

  129. Sharief MK, Sander JW, Shorvon SD. Acute encephalopathy with vigabatrin. Lancet (London, England). 1993;342(8871):–619.

  130. Canovas Martinez A, Ordovas Baines JP, Beltran Marques M, Escriva Aparisi A, Delgado CF. Vigabatrin-associated reversible acute psychosis in a child. Ann Pharmacother. 1995;29(11):1115–7.

    Article  CAS  PubMed  Google Scholar 

  131. Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology. 1999;53(7):1503–11.

    Article  CAS  PubMed  Google Scholar 

  132. Xavier M, Bento MS, Pereira DP, De Almeida JM. Acute psychotic disorder associated with vigabatrin. Acta medica portuguesa. 2000;13(3):111–4.

    CAS  PubMed  Google Scholar 

  133. Kellermann K, Soditt V, Rambeck B, Klinge O. Fatal hepatotoxicity in a child treated with vigabatrin. Acta Neurol Scand. 1996;93(5):380–1.

    Article  CAS  PubMed  Google Scholar 

  134. de Krom MC, Verduin N, Visser E, Kleijer M, Scholtes F, De Groen JH. Status epilepticus during vigabatrin treatment: a report of three cases. Seizure. 1995;4(2):159–62.

    Article  PubMed  Google Scholar 

  135. Garcia Pastor A, Garcia-Zarza E, Peraita AR. Acute encephalopathy and myoclonic status induced by vigabatrin monotherapy. Neurologia (Barcelona, Spain). 2000;15(8):Ͱ–4.

    Google Scholar 

  136. Dieterle L, Becker EW, Berg PA, Berkenfeld R, Reinshagen G. Allergic vasculitis caused by Vigabatrin. Nervenarzt. 1994;65(2):122–4.

    CAS  PubMed  Google Scholar 

  137. Papadeas E, Polychronopoulos P, Papathanasopoulos P, Frimas C, Pharmakakis N, Paschalis C. Sensorineural hearing loss: a reversible effect of vigabatrin. Neurology. 2003;61(7):1020–1.

    Article  CAS  PubMed  Google Scholar 

  138. Williams A, Sekaninova S, Coakley J. Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin. J Paediatr Child Health. 1998;34(4):395–7.

    Article  CAS  PubMed  Google Scholar 

  139. Karabiyik L. Acute vigabatrin poisoning in a patient with epilepsy. J Appl Res. 2003;3(2):156–8.

    Google Scholar 

  140. Bachmann D, Ritz R, Wad N, Haefeli WE. Vigabatrin dosing during haemodialysis. Seizure. 1996;5(3):239–42.

    Article  CAS  PubMed  Google Scholar 

  141. Jacqz-Aigrain E, Guillonneau M, Rey E, Macher MA, Montes C, Chiron C, et al. Pharmacokinetics of the S(+) and R(−) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. Br J Clin Pharmacol. 1997;44(2):183–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. ONFI® (clobazam) [PDF]. [updated 11/2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202067s002,203993s002lbl.pdf.

  143. Sankar R. GABA(a) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS drugs. 2012;26(3):229–44.

    Article  CAS  PubMed  Google Scholar 

  144. Rupp W, Badian M, Christ O, Hajdu P, Kulkarni RD, Taeuber K, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol. 1979;7(Suppl 1):51s–7s.

    Article  PubMed  PubMed Central  Google Scholar 

  145. de Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013;35(1):30–47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  146. Tolbert D, Bekersky I, Chu HM, Ette EI. An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics. J Clin Pharmacol. 2016;56(2):213–22.

    Article  CAS  PubMed  Google Scholar 

  147. Parmeggiani A, Posar A, Sangiorgi S, Giovanardi-Rossi P. Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. Brain Dev. 2004;26(1):63–6.

    Article  PubMed  Google Scholar 

  148. Zifkin B, Sherwin A, Andermann F. Phenytoin toxicity due to interaction with clobazam. Neurology. 1991;41(2 ( Pt 1):313–4.

    Article  CAS  PubMed  Google Scholar 

  149. Naccarato M, Yoong D, Kovacs C, Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17(3):589–92.

    Article  CAS  PubMed  Google Scholar 

  150. Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication with negative myoclonus after the addition of clobazam. Epilepsia. 1998;39(10):1115–8.

    Article  CAS  PubMed  Google Scholar 

  151. Faulkner MA. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox-Gastaut syndrome. Ther Clin Risk Manag. 2015;11:905–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Klehm J, Thome-Souza S, Sanchez Fernandez I, Bergin AM, Bolton J, Harini C, et al. Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol. 2014;51(1):60–6.

    Article  PubMed  Google Scholar 

  153. Ng YT, Conry J, Mitchell WG, Buchhalter J, Isojarvi J, Lee D, et al. Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: post hoc analyses of short- and long-term clinical trial results. Epilepsy Behav. 2015;46:221–6.

    Article  PubMed  Google Scholar 

  154. Aylett SE, Cross H, Berry D. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. Dev Med Child Neurol. 2006;48(7):612–5.

    Article  PubMed  Google Scholar 

  155. Dang CD, Beets-Shay L, Kahn EC. Toxic epidermal necrolysis triggered by clobazam: a case report in a 13-year-old girl. Pediatr Dermatol. 2015;32(3):e102–3.

    Article  PubMed  Google Scholar 

  156. Iwasaki T, Miura H, Sunaoshi W, Hosoda N, Takei K, Katayama F. A case of intractable epilepsy showing frequent gelastic seizures by administration of clobazam. No to hattatsu Brain Dev. 2003;35(5):406–10.

    Google Scholar 

  157. Caramaschi P, Biasi D, Carletto A, Manzo T, Bambara LM. Clobazam-induced systemic lupus erythematosus. Clin Rheumatol. 1995;14(1):116.

    Article  CAS  PubMed  Google Scholar 

  158. Rauber-Luethy C, Gross S, Hofer KE, Hoffmann-Walbeck P, Prasa D, Farber E, et al. Annual Meeting of the North American Congress of Clinical Toxicology (NACCT). Abstract: Favorable acute toxicity profile of clobazam in overdose. Clin Toxicol. 2013;51(7):575–724.

  159. Proenca P, Teixeira H, Pinheiro J, Marques EP, Vieira DN. Forensic intoxication with clobazam: HPLC/DAD/MSD analysis. Forensic Sci Int. 2004;143(2–3):205–9.

    Article  CAS  PubMed  Google Scholar 

  160. Pok PR, Mauras M, De Saint Leger MN, Kuhlmann E, Charpenel-Durat C, Navarette C, et al. Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate. Legal medicine (Tokyo, Japan). 2010;12(6):300–4.

    Article  CAS  Google Scholar 

  161. POTIGA (ezogabine) [PDF]. 2011 [updated 05/2016. 2016]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022345s011lbl.pdf.

  162. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012;53(3):412–24.

    Article  CAS  PubMed  Google Scholar 

  163. Treven M, Koenig X, Assadpour E, Gantumur E, Meyer C, Hilber K, et al. The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors. Epilepsia. 2015;56(4):647–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol. 2002;42(2):175–82.

    Article  CAS  PubMed  Google Scholar 

  165. Tompson DJ, Crean CS. Clinical pharmacokinetics of retigabine/ezogabine. Curr Clin Pharmacol. 2013;8(4):319–31.

    Article  CAS  PubMed  Google Scholar 

  166. Amabile CM, Vasudevan A. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures. Pharmacotherapy. 2013;33(2):187–94.

    Article  CAS  PubMed  Google Scholar 

  167. Tompson DJ, Buraglio M, Bullman J, Crean CS, Rayner K. Effect of hemodialysis on pharmacokinetics of ezogabine/retigabine and its N-acetyl metabolite in patients with end stage renal disease. Curr Clin Pharmacol. 2014;9(4):319–25.

    Article  CAS  PubMed  Google Scholar 

  168. Tompson DJ, Crean CS. The interaction potential of retigabine (ezogabine) with other antiepileptic drugs. Curr Clin Pharmacol. 2014;9(2):148–56.

    Article  CAS  PubMed  Google Scholar 

  169. French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76(18):1555–63.

    Article  CAS  PubMed  Google Scholar 

  170. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68(15):1197–204.

    Article  CAS  PubMed  Google Scholar 

  171. Brickel N, Gandhi P, VanLandingham K, Hammond J, DeRossett S. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012;53(4):606–12.

    Article  CAS  PubMed  Google Scholar 

  172. Ezogabine (Potiga) toxicity. The Medical letter on drugs and therapeutics. 2013;55(1430):96.

  173. Schedules of controlled substances: placement of ezogabine into Schedule V. Final rule. Fed Regist 2011;76(241):77895–99.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Indiana University, 355 W. 16th Street, Suite 3200, Indianapolis, IN, 46202, USA

    Paul LaPenna & Laura M. Tormoehlen

  2. Department of Emergency Medicine, Indiana University, Indianapolis, IN, USA

    Laura M. Tormoehlen

Authors
  1. Paul LaPenna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura M. Tormoehlen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura M. Tormoehlen.

Ethics declarations

Conflict of Interest

None.

Sources of Funding

None.

Conflict Delineations

None.

Additional information

Dr. Tormoehlen presented a version of this paper as part of a lecture presentation at the ACMT Annual Scientific Meeting – “Targets and Toxicities of Newer Anticonvulsants.”

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

LaPenna, P., Tormoehlen, L.M. The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs. J. Med. Toxicol. 13, 329–342 (2017). https://doi.org/10.1007/s13181-017-0626-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-017-0626-4

Keywords

Search

Navigation